Join

Compare · RELV vs TRIL

RELV vs TRIL

Side-by-side comparison of Reliv' International, Inc. (RELV) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both RELV and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
  • TRIL carries a market cap of $1.94B.
  • TRIL has more recent analyst coverage (5 ratings vs 0 for RELV).
MetricRELVTRIL
Company
Reliv' International, Inc.
Trillium Therapeutics Inc.
Price
-
$19.30-3.45%
Market cap
-
$1.94B
1M return
-
-3.79%
1Y return
-
-5.02%
Industry
Major Pharmaceuticals
Major Pharmaceuticals
Exchange
NASDAQ
NASDAQ
IPO
n/a
n/a
News (4w)
0
0
Recent ratings
0
5
RELV

Reliv' International, Inc.

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.

TRIL

Trillium Therapeutics Inc.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.